Biogen may be meeting tomorrow, March 22, to discuss my case. Please help me by emailing Biogen (see email addresses below) to tell them:
 
The FDA regulatory review is not endangered by offering me, Lisa Stockman-Mauriello, access to tofersen. The concept of waiting for expanded access until after the trial is over, is essentially handing me a death sentence, when it doesn’t need to be one. Expanded access for me is an absolute option. There are only a small handful of Americans with the SOD1 gene who are diagnosed with the “rapid advancing AV5 variant.” Biogen does not need to choose between thousands, it is handfuls of lives it can save.
 
Watch my plea to them in my video.
 
patientcenter@biogen.com
Public.affairs@biogen.com
IR@biogen.com
PublicAffairs.EU@biogen.com
partnering@biogen.com
medinfo@biogen.com